Sunday, 22 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· October 22, 2026

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy

View original at finance.yahoo.com
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Vor Biopharma Annualized eGFR slope of -0.6 vs…
Opening lines of the source · Yahoo Finance · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • At 104 weeks TELIGAN demonstrated substantial proteinuria reduction and durable kidney protection; annualized eGFR slope approaching zero, lower rates of kidney function deterioration and sustained proteinuria reductions after transition to every-other-week dosing reinforce telitacicept's clinical potential and add to evidence supporting dual BAFF/APRIL inhibition.

    60% confidence
  • TELIGAN met the Stage B primary endpoint, with a statistically significant difference in annualized eGFR slope through 104 weeks versus placebo.

    60% confidence
  • Telitacicept reduced the risk of confirmed ≥30% and ≥40% eGFR declines by 89% and 81%, respectively.

    60% confidence

Cited in these Via News reports

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy: Source | Via News | vianews.eu